Related Experiment Video

Updated: Oct 3, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.2K

Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?

Emma E Newton1, Lauren E Mueller1, Scout M Treadwell1

  • 1Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.

Cancers
|February 15, 2022
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive and hard to treat. Emerging immunotherapies targeting immune pathways show promise for improving survival and altering future treatment for TNBC patients.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype known for heterogeneity and metastasis.
  • Lack of targetable receptors makes chemotherapy and surgery the primary, yet often ineffective, treatments.
  • Chemotherapy resistance and tumor recurrence are significant challenges in TNBC management.

Purpose of the Study:

  • To review identified immune pathways in TNBC.
  • To explore the role of these pathways as targets for novel therapeutic strategies.
  • To discuss the impact of emerging immunotherapies on TNBC treatment.

Main Methods:

  • Literature review of current research on TNBC immunology and treatment.
  • Analysis of immune pathways implicated in TNBC progression and treatment resistance.
  • Evaluation of preclinical and clinical data for immunotherapeutic agents.

Main Results:

  • Several immune pathways in TNBC have been identified as potential therapeutic targets.
  • Inhibiting key pathways in cellular growth, DNA repair, epithelial-mesenchymal transition, and immunosuppression demonstrates improved survival.
  • Emerging immunotherapies are beginning to reshape treatment paradigms for TNBC.

Conclusions:

  • Immunotherapy offers a promising avenue for overcoming treatment resistance in TNBC.
  • Targeting specific immune pathways holds potential for improving patient outcomes.
  • Continued research in immunotherapy and neoadjuvant therapy is crucial for advancing TNBC care.
Keywords:
biological targetsimmunotherapytreatment resistancetriple-negative breast cancer

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K